Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL

NCT06828991 is registered in ClinicalTrials.gov with Danielle Wallace as lead sponsor.

NCT NCT06828991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06828991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL
Lead sponsor
Danielle Wallace
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2025
Completion date
April 30, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl)